<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144815" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Increasing Awareness about Pulmonary Arterial Hypertension Treatment for Nurses (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kingman</surname>
            <given-names>Martha</given-names>
          </name>
          <aff>University of Texas Southwestern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaqar</surname>
            <given-names>Sarosh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Martha Kingman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarosh Vaqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144815.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pulmonary hypertension is a condition in which the blood pressure in the arteries of the lungs and the right side of the heart becomes elevated. This may be due to blockage, narrowing, or damage to the blood vessels of the lungs, which increases pulmonary blood pressure.&#x000a0;Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH) characterized by increased resistance in the pulmonary circulation, which is caused by progressive pulmonary artery remodeling and constriction of the pulmonary vasculature.<xref ref-type="bibr" rid="article-144815.r1">[1]</xref><xref ref-type="bibr" rid="article-144815.r2">[2]</xref>&#x000a0;</p>
        <p>In the current era of PAH management, one-year survival rates have increased to 86% to 90% from 65% in the 1980s, and average long-term survival has increased to 6 years from 2.8 years.<xref ref-type="bibr" rid="article-144815.r3">[3]</xref></p>
        <p>This is due to the advancement of targeted medical therapy for PAH. Research that focused on phenotyping and understanding the pathophysiology of PAH at a cellular and genetic level has led to the use of precision medicine and the development of medications that may prevent or reverse pulmonary vascular remodeling associated with this disease.<xref ref-type="bibr" rid="article-144815.r3">[3]</xref></p>
        <p>Without treatment, pulmonary hypertension can slowly progress and become fatal. Treatment is primarily aimed at the reduction of symptoms and the improvement of quality of life.&#x000a0;New York Heart Association (NYHA) functional class remains an important predictor of future survival in patients. Disease progression (e.g., decline &#x0003e;15% in the 6-minute walking distance (6MWD) and decline in NYHA functional class) are strong predictors of mortality in PAH.<xref ref-type="bibr" rid="article-144815.r4">[4]</xref><xref ref-type="bibr" rid="article-144815.r5">[5]</xref>&#x000a0;</p>
        <p>PAH-related hospitalization is associated with rehospitalization and worse survival.<xref ref-type="bibr" rid="article-144815.r6">[6]</xref> Thus, early diagnosis and intervention are critical to improving outcomes in patients with this disease.</p>
        <p>Care of patients with PAH is multimodal and requires frequent nursing interventions for patient education, monitoring, and clinical assessments. A recent study reported that nurses at a specialized outpatient center treating patients with PH were highly qualified and skilled but still expressed a desire for in-depth and continued training.<xref ref-type="bibr" rid="article-144815.r7">[7]</xref>&#x000a0;This activity seeks to highlight the medical care of patients with PAH and emphasizes the role of nurses in their care.&#x000a0;</p>
      </sec>
      <sec id="article-144815.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Diagnosis</bold>
</p>
        <p>The diagnosis of PAH can be challenging. Patients often present with a variety of progressive, nonspecific symptoms such as fatigue, chest pain, syncope, or exertional shortness of breath, all of which suggest various conditions. However, significant progress in understanding the etiology, epidemiology, pathophysiology, and prognosis of PAH has been made over the last few years in both adult and pediatric patients.<xref ref-type="bibr" rid="article-144815.r8">[8]</xref></p>
        <p>The current diagnostic gold standard for PAH is right heart catheterization, which shows a mean pulmonary arterial pressure (mPAP) &#x0003e; 20 mmHg.<xref ref-type="bibr" rid="article-144815.r8">[8]</xref><xref ref-type="bibr" rid="article-144815.r9">[9]</xref><xref ref-type="bibr" rid="article-144815.r10">[10]</xref>&#x000a0;However, initial testing is often with transthoracic echocardiography (TTE), which results in referral for right heart catheterization when estimated PAP is elevated and/or there is right ventricular enlargement or dysfunction.<xref ref-type="bibr" rid="article-144815.r11">[11]</xref>&#x000a0;</p>
        <p>An initial suspicion for PAH based on patient presentation and symptoms is necessary for referral for diagnostic testing, ideally at a pulmonary hypertension expert center. Accurate diagnosis and classification of PAH are necessary to initiate timely treatment to increase survival rates and decrease overall morbidity.</p>
        <p>
<bold>Initiating Therapy and Improving Patient Outcomes</bold>
</p>
        <p>The World Symposium on Pulmonary Hypertension (WSPH) published new treatment guidelines for the management of PAH in 2019.<xref ref-type="bibr" rid="article-144815.r9">[9]</xref>&#x000a0;These treatment guidelines begin with confirmation of PAH at an expert center by right heart catheterization. Patients who do not respond to acute vasoreactivity testing are then categorized as low, intermediate, or high risk using one of several available risk calculators.</p>
        <p>There is a limited role for monotherapy in patients who are deemed low risk, while the majority of patients require combination therapy, most often with an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE5i). Patients at high risk for early mortality are also referred for lung transplant evaluation and started on an intravenous prostanoid therapy. Early regular follow-up of patients is recommended to identify early disease progression to escalate care.</p>
        <p>Treatment options for PAH include prostacyclin therapies (intravenous epoprostenol; inhaled iloprost; intravenous, subcutaneous, inhaled, oral treprostinil, and selexipag), endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, oral tadalafil), and one soluble guanylate cyclase stimulator (riociguat).</p>
        <p>Several new therapies are in clinical trials, some of which have the potential to be disease-modifying agents. These include sotatercept, a novel fusion protein that aims to re-balance the pro-proliferative and anti-proliferative pathways in the pulmonary vasculature. Also under investigation are targeted therapies for chronic thromboembolic pulmonary hypertension (CTEPH); and targeted therapies for right ventricular (RV) failure.<xref ref-type="bibr" rid="article-144815.r12">[12]</xref><xref ref-type="bibr" rid="article-144815.r13">[13]</xref><xref ref-type="bibr" rid="article-144815.r14">[14]</xref>&#x000a0;</p>
        <p>Prior research in combination therapies has created a paradigm shift in the treatment of PAH away from sequential therapy to combination therapy for newly diagnosed PAH patients.<xref ref-type="bibr" rid="article-144815.r15">[15]</xref></p>
        <p>Initiating therapy for a patient with PAH can also be challenging. In some instances, therapy may not be readily available via formulary, and in most cases, prior approval from the insurance company may be required. Furthermore, challenges may arise in the safe and effective utilization of parenteral prostacyclin medications.</p>
        <p>Both the US and the European guidelines endorse patient and practitioner education of potential medical risk factors and behavioral modifications as important aspects of management.<xref ref-type="bibr" rid="article-144815.r16">[16]</xref>&#x000a0;These guidelines also note that PAH patients should be referred to an expert referral center to manage their condition.</p>
        <p>Despite these recommendations, studies have shown that patients referred to PH centers for diagnosis and treatment are often referred late in the course of their disease, have been misdiagnosed, and are inappropriately prescribed medications.<xref ref-type="bibr" rid="article-144815.r17">[17]</xref>&#x000a0;It has been reported in the literature that a re-evaluation of educational efforts is required to improve awareness and the care and outcome of patients diagnosed as having PAH.</p>
        <p>Because PAH is a rare condition, the number of patients receiving specialized therapy in the hospital setting at any given time is low. Clinicians who are not PAH specialists may have limited knowledge of the complex dosing and safety profiles of these medications. This also underscores the need for additional education on early diagnosis and initiation of therapy.</p>
        <p>
<bold>Current Treatment Options</bold>
</p>
        <p>Several therapies that delay disease progression and reduce the risk of hospitalization for individuals with PAH have been developed in recent years. These treatment options target the endothelin-1, prostacyclin, and nitric oxide pathways.<xref ref-type="bibr" rid="article-144815.r3">[3]</xref><xref ref-type="bibr" rid="article-144815.r15">[15]</xref>&#x000a0;</p>
        <p>The therapies include the prostacyclin analogs intravenous epoprostenol; inhaled iloprost; intravenous, subcutaneous, inhaled, oral treprostinil and selexipag, endothelin receptor antagonists: oral ambrisentan, oral bosentan, oral macitentan, phosphodiesterase-5 inhibitors: intravenous and oral sildenafil, oral tadalafil, and the soluble guanylate cyclase stimulators: oral riociguat.<xref ref-type="bibr" rid="article-144815.r18">[18]</xref><xref ref-type="bibr" rid="article-144815.r19">[19]</xref><xref ref-type="bibr" rid="article-144815.r20">[20]</xref><xref ref-type="bibr" rid="article-144815.r21">[21]</xref>&#x000a0;</p>
        <p>Each of these medications has its own side effect profile and method of dosing and administration, and familiarity with the adverse events associated with each drug is necessary for timely recognition and optimal treatment of the patient with PAH.</p>
        <p>
<bold>Emerging Therapies and Treatment Pathways</bold>
</p>
        <p>The growing understanding of the pathophysiology of PAH is identifying new treatment pathways that target the underlying mechanisms of the disease. Endothelial progenitor cells (EPCs) are released by the bone marrow and play a role in revascularization and tissue repair of areas where vascular injury or ischemia has occurred.</p>
        <p>In addition to in situ proliferation of vascular cells, studies over the past 20 years have revealed a role for circulating and resident vascular cells in pulmonary vascular remodeling, unveiling therapeutic potential for circulating EPCs and mesenchymal stem cells.<xref ref-type="bibr" rid="article-144815.r22">[22]</xref></p>
        <p>The phase 1 Pulmonary Hypertension and Angiogenic Cell Therapy (PHACeT) trial found that eNOS-transfected early outgrowth EPCs delivered into the right atrium of 7 patients with idiopathic PAH showed no evidence of short-term hemodynamic deterioration, a trend toward short-term hemodynamic improvements, and sustained increases in exercise capacity at 3 and 6 months. One death occurred immediately after discharge in a patient with severe, end-stage disease.<xref ref-type="bibr" rid="article-144815.r23">[23]</xref>&#x000a0;</p>
        <p>The phase II Study of Angiogenic cell therapy for Progressive Pulmonary Hypertension: Intervention with Repeat dosing of eNOS-enhanced EPCs (SAPPHIRE) trial is evaluating the efficacy and safety of angiogenic therapy to restore the microvasculature with repeat dosing of autologous EPCs transfected with human eNOS in patients with refractory PAH. Forty-five patients will be randomized to receive four doses of eNOS gene-enhanced autologous EPCs monthly. The primary endpoint is the difference in 6MWD at six months between participants receiving the eNOS-EPCs compared to the placebo. This Canadian-based trial is currently recruiting patients; trial results are anticipated in 2023. (NCT03001414)</p>
        <p>An emerging non-prostanoid prostacyclin receptor agonist, ralinepag, has been studied in 61 PAH patients receiving either mono or dual PAH-targeted background therapy. These patients were randomized to receive ralinepag (n=40) or a placebo (n=21). The ralinepag was started at a dose of 10 &#x003bc;g twice daily and increased as tolerated over 9-weeks to a maximum total daily dose of 600 &#x003bc;g (300 &#x003bc;g twice daily). At week 22, ralinepag was shown to significantly decrease PVR by 163.9 dyn&#x000b7;s&#x000b7;cm&#x02212;5 compared to an increase of 0.7 dyn&#x000b7;s&#x000b7;cm&#x02212;5 with placebo. The data showed that ralinepag reduced PVR in patients on monotherapy by 41% and patients on dual combination therapy by 59% compared to placebo.<xref ref-type="bibr" rid="article-144815.r24">[24]</xref></p>
        <p>Several other new therapies are in clinical trials or are otherwise emerging. These include sotatercept, a novel fusion protein; targeted therapies for CTEPH; and targeted therapies for right ventricular (RV) failure.<xref ref-type="bibr" rid="article-144815.r12">[12]</xref><xref ref-type="bibr" rid="article-144815.r13">[13]</xref><xref ref-type="bibr" rid="article-144815.r14">[14]</xref>&#x000a0;Additionally, recent research into combination therapies has created a paradigm shift in the treatment of PAH.<xref ref-type="bibr" rid="article-144815.r15">[15]</xref></p>
        <p>Sotatercept binds activins and growth differentiation factors to restore the balance between growth-promoting and growth-inhibiting signaling pathways. In a 24-week multicenter randomized trial of 106 adults with PAH on background therapy, sotatercept treatment reduced pulmonary vascular resistance and was also associated with a decrease in N-terminal pro-B-type natriuretic peptide levels.<xref ref-type="bibr" rid="article-144815.r12">[12]</xref></p>
        <p>Another pathway that has recently received attention as a potential therapeutic target in PAH is that of autoimmunity and inflammation. It has been widely recognized that patients with connective tissue diseases or viral infections&#x02014;including COVID-19&#x02014;are more susceptible to PAH.<xref ref-type="bibr" rid="article-144815.r25">[25]</xref><xref ref-type="bibr" rid="article-144815.r26">[26]</xref>&#x000a0;</p>
        <p>However, recent evidence now supports that patients with idiopathic PAH with no known autoimmune diseases also have auto-antibodies. Local immunoglobulin production may play a role in association with maladaptive immune responses in pulmonary tissue, and this provides a theoretical basis for future drug development and precision therapies in patients with PAH.<xref ref-type="bibr" rid="article-144815.r25">[25]</xref></p>
        <p>
<bold>Telehealth and Remote Monitoring</bold>
</p>
        <p>It has been noted that patients with PAH benefit from intensive, continuous clinical monitoring to guide the escalation of therapy. During the COVID-19 pandemic, the need for physical distancing has seen a rise in the use of various telehealth modalities, which may apply in unique ways to patients with PAH. The uniquely high risk for rapid deterioration in PAH demands a high degree of sensitivity to detect changes in functional assessments.<xref ref-type="bibr" rid="article-144815.r27">[27]</xref></p>
        <p>Small studies of short-term duration have shown a reduction in hospitalization rates using telehealth monitoring for patients with PAH.<xref ref-type="bibr" rid="article-144815.r28">[28]</xref>&#x000a0;Furthermore, there has been an expanding role for implantable devices to monitor heart failure and PH, with changes in hemodynamic parameters (which often occur before symptoms) used to guide changes in therapy.<xref ref-type="bibr" rid="article-144815.r26">[26]</xref>&#x000a0;Additional study and understanding are needed to validate remote monitoring parameters in patients with PAH.<xref ref-type="bibr" rid="article-144815.r28">[28]</xref><xref ref-type="bibr" rid="article-144815.r29">[29]</xref></p>
      </sec>
      <sec id="article-144815.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The role of nurses in the management of patients with PAH is pivotal. Although these therapies significantly improve clinical outcomes, they are associated with adverse reactions such as flushing, headache, and hypotension. Frequent and accurate measurement of vital signs is required in patients receiving intravenous therapies to avoid severe hypotension.</p>
        <p>Moreover, there is an increased risk of falls secondary to deconditioning, syncope, and presyncope in these patients. Additionally, patients receiving continuous I.V. infusions are at an increased risk for catheter-related bloodstream infections. Nurses play a pivotal role in monitoring the insertion sites for these catheters for potential infections.</p>
        <p>Given the complex and progressive nature of this disease, patients require extensive education on the expected clinical course of the disease, potential adverse effects of therapies, and preventive measures to limit adverse outcomes.&#x000a0;Nurses play an integral role in educating and monitoring these patients to optimize clinical outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-144815.s4" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pulmonary hypertension is a complex clinical syndrome with high morbidity and mortality. It requires a multifaceted treatment approach, including patient education, pharmacologic management, and invasive diagnostic/therapeutic procedures to optimize clinical outcomes.</p>
        <p>Specialty-trained nurses are essential to the interprofessional team caring for patients with PH. They educate the patient on the importance of fall preventive measures, compliance with oxygen therapy, lifestyle modifications to maintain adequate nutrition and function, as well as medical compliance to help improve morbidity and mortality associated with this disease. Specialized nurses for in-home care are especially important given the poor mobility of these patients. They can help evaluate the patient in the community setting and ensure the delivery of adequate outpatient treatment.</p>
        <p>The clinical pharmacists assist the medical providers by reviewing patient medication lists and decreasing potential adverse drug-drug interactions for these patients. Primary care medical providers and pulmonologists must coordinate care to minimize any adverse outcomes of medical therapy and prevent the progression of this disease. A collaborative interprofessional team can significantly improve the quality of life for patients with PH and decrease mortality. [Level 5]</p>
      </sec>
      <sec id="article-144815.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144815&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144815">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144815/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144815">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144815.s6">
        <title>References</title>
        <ref id="article-144815.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodson</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Arterial Hypertension.</article-title>
            <source>Heart Fail Clin</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-269</page-range>
            <pub-id pub-id-type="pmid">29966625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burger</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>DuBrock</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Cartin-Ceba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Topic-Based, Recent Literature Review on Pulmonary Hypertension.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>12</issue>
            <fpage>3109</fpage>
            <page-range>3109-3121</page-range>
            <pub-id pub-id-type="pmid">34479734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshwal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sulica</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Advances in the management of pulmonary arterial hypertension.</article-title>
            <source>J Investig Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>1270</fpage>
            <page-range>1270-1280</page-range>
            <pub-id pub-id-type="pmid">34580123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Poms</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Muros-Le Rouzic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Five-Year outcomes of patients enrolled in the REVEAL Registry.</article-title>
            <source>Chest</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>1043</fpage>
            <page-range>1043-54</page-range>
            <pub-id pub-id-type="pmid">26066077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Schilz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chakinala</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Hartline</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.</article-title>
            <source>Chest</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>147</volume>
            <issue>2</issue>
            <fpage>484</fpage>
            <page-range>484-494</page-range>
            <pub-id pub-id-type="pmid">25320967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burger</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Safford</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.</article-title>
            <source>Chest</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>1263</fpage>
            <page-range>1263-1273</page-range>
            <pub-id pub-id-type="pmid">24901386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivarsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjellstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Novel Insight into How Nurses Working at PH Specialist Clinics in Sweden Perceive Their Work.</article-title>
            <source>Healthcare (Basel)</source>
            <year>2020</year>
            <month>Jun</month>
            <day>19</day>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32575509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaestner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Apitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lammers</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Cardiac catheterization in pediatric pulmonary hypertension: a systematic and practical approach.</article-title>
            <source>Cardiovasc Diagn Ther</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>1102</fpage>
            <page-range>1102-1110</page-range>
            <pub-id pub-id-type="pmid">34527536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30545968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelzinis</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1552</fpage>
            <page-range>1552-1564</page-range>
            <pub-id pub-id-type="pmid">34344595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Topy&#x00142;a-Putowska</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wysoki&#x00144;ski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Jul</month>
            <day>22</day>
            <volume>10</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">34362015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JSR</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Escribano Subias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Manimaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>de Oliveira Pena</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <collab>PULSAR Trial Investigators</collab>
            </person-group>
            <article-title>Sotatercept for the Treatment of Pulmonary Arterial Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>384</volume>
            <issue>13</issue>
            <fpage>1204</fpage>
            <page-range>1204-1215</page-range>
            <pub-id pub-id-type="pmid">33789009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Can Respir J</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>1626971</fpage>
            <pub-id pub-id-type="pmid">34512819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernal-Ramirez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Vesga</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Talamilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quiroga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garza-Cervantes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>L&#x000e1;zaro-Alfaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jerjes-Sanchez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Henr&#x000ed;quez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Rivas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pedrozo</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction.</article-title>
            <source>Oxid Med Cell Longev</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>9993060</fpage>
            <pub-id pub-id-type="pmid">34497685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gale</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The evolving treatment landscape of pulmonary arterial hypertension.</article-title>
            <source>Am J Manag Care</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3 Suppl</issue>
            <fpage>S42</fpage>
            <page-range>S42-S52</page-range>
            <pub-id pub-id-type="pmid">33710843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramjug</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weatherald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Foris</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bokan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godinas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly.</article-title>
            <source>ERJ Open Res</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33083438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dea&#x000f1;o</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Glassner-Kolmin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubenfire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Visovatti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.</article-title>
            <source>JAMA Intern Med</source>
            <year>2013</year>
            <month>May</month>
            <day>27</day>
            <volume>173</volume>
            <issue>10</issue>
            <fpage>887</fpage>
            <page-range>887-93</page-range>
            <pub-id pub-id-type="pmid">23568223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steriade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seferian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ja&#x000ef;s</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Savale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jutant</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">24728960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corris</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Klinger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Langleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Naeije</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jansa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scelsi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vizza</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colorado</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.</article-title>
            <source>Eur Respir J</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28889107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kiely</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kotlyar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McSwain</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Laliberte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arneson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <collab>FREEDOM-C2 Study Team</collab>
            </person-group>
            <article-title>Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.</article-title>
            <source>Chest</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>144</volume>
            <issue>3</issue>
            <fpage>952</fpage>
            <page-range>952-958</page-range>
            <pub-id pub-id-type="pmid">23669822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorensen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wehland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kruger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nassef</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Infanger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.</article-title>
            <source>Curr Pharm Des</source>
            <year>2017</year>
            <volume>23</volume>
            <issue>34</issue>
            <fpage>5191</fpage>
            <page-range>5191-5199</page-range>
            <pub-id pub-id-type="pmid">28891448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dierick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Solinc</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bignard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soubrier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nadaud</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>May</month>
            <day>28</day>
            <volume>10</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">34071347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Langleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kutryk</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Camack</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galipeau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Courtman</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial.</article-title>
            <source>Circ Res</source>
            <year>2015</year>
            <month>Sep</month>
            <day>11</day>
            <volume>117</volume>
            <issue>7</issue>
            <fpage>645</fpage>
            <page-range>645-54</page-range>
            <pub-id pub-id-type="pmid">26195220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ristic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shanahan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Escribano Sub&#x000ed;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31391223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Autoimmunity in Pulmonary Arterial Hypertension: Evidence for Local Immunoglobulin Production.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>680109</fpage>
            <pub-id pub-id-type="pmid">34621794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cascino</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kanthi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>342</fpage>
            <page-range>342-349</page-range>
            <pub-id pub-id-type="pmid">34127622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yacoub</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The expanding role of implantable devices to monitor heart failure and pulmonary hypertension.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>770</fpage>
            <page-range>770-779</page-range>
            <pub-id pub-id-type="pmid">30367136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wesley Milks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-182</page-range>
            <pub-id pub-id-type="pmid">33414063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144815.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Garcia</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fatehi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Varnfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karunanithi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cordina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feenstra</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Use of eHealth in the management of pulmonary arterial hypertension: review of the literature.</article-title>
            <source>BMJ Health Care Inform</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32928780</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
